DOCSLIB.ORG

Ep 0665009 B1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ep 0665009 B1 Europäisches Patentamt (19) European Patent Office Office européen des brevets (11) EP 0 665 009 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int. Cl.7: A61K 9/00, A61K 9/14 of the grant of the patent: 16.02.2000 Bulletin 2000/07 (86) International application number: PCT/JP93/01469 (21) Application number: 93922625.4 (87) International publication number: (22) Date of filing: 13.10.1993 WO 94/08561 (28.04.1994 Gazette 1994/10) (54) CRYSTALLINE CONDITION DISLOCATING METHOD VERFAHREN ZUR VERSCHIEBUNG EINES KRISTALLZUSTANDES PROCEDE DE DISLOCATION D'UN ETAT CRISTALLIN (84) Designated Contracting States: (74) Representative: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL Vogeser, Werner, Dipl.-Ing. et al PT SE Patent- und Rechtsanwälte Hansmann, Vogeser, Dr. Boecker, (30) Priority: 14.10.1992 JP 30308592 Alber, Dr. Strych, Liedl Albert-Rosshaupter-Strasse 65 (43) Date of publication of application: 81369 München (DE) 02.08.1995 Bulletin 1995/31 (56) References cited: (73) Proprietor: EP-A- 0 177 428 EP-A- 0 490 768 NIPPON SHINYAKU COMPANY, LIMITED EP-A- 0 580 860 JP-A- 51 139 613 Minami-ku Kyoto-shi Kyoto 601 (JP) JP-A- 60 190 723 (72) Inventors: • Journal of Pharmaceutical Sciences, Vol. 62, No. • NAKAMICHI, Kouichi 1, (January 1973), F.W. GOODHART et al., Koga-gun, Shiga 520-32 (JP) "Design and Use of a Laboratory Extruder for • IZUMI, Shougo Pharmaceutical Granulations", p. 133-136. Kameoka-shi, Kyoto 621 (JP) • OKA, Masaaki Hirakata-shi, Osaka 573 (JP) Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 0 665 009 B1 Printed by Xerox (UK) Business Services 2.16.7/3.6 12EP 0 665 009 B1 Description (1) from a crystallizable active substance in metast- able crystalline state or in amorphous solid state to TECHNICAL FIELD stable crystals, (2) a crystallizable active substance in stable crys- [0001] This invention relates to a method of inducing 5talline state or in amorphous solid state to metasta- a transition of crystalline state in a crystallizable medic- ble crystals, inal substance. (3) a crystallizable active substance in stable crys- [0002] As used in this specification, the term 'stable talline state or in metastable crystalline state to an crystal' means any crystal that is in thermodynamically amorphous solid, or stable crystalline state and the term 'metastable crystal' 10 (4) a crystallizable active substance in heteroge- means any crystal that is in thermodynamically unstable nous crystalline state to homogeneous crystals. crystalline state. The term 'crystalline state' is used referring to any of stable crystal, metastable crystal and [0007] The inventors of this invention found that the amorphous (noncrystalline) solid. The term 'heteroge- above-mentioned object can be accomplished by utiliz- nous crystal' means a crystal not in a singular crystal- 15 ing an extruder which enables a continuous processing line state. of the load and have arrived at the present invention. [0003] The term 'extruder' means any screw extruder [0008] In the pharmaceutical field, few technologies that is in broad use chiefly in food industry for the utilizing an extruder are known. processing of food materials (cereals, proteins, animal [0009] At this junction, the mechanism of the main meat, fish meat, etc.). 20 part (work processing part) of the extruder is briefly described. Generally the main part of an extruder com- BACKGROUND ART prises, as illustrated in Fig. 1, a cylindrical structure called 'barrel', a die which corresponds to a delivery [0004] The conventional technology for inducing a port, and a screw. The barrel usually comprises a plural- transition of crystalline state in a medicinal substance 25 ity of unit barrels and the screw extends through them. includes recrystallization, heating, freeze-drying, pul- The screw is available in various types, namely trape- verizing and so on. Document EP-A-0580860 (docu- zoidal screw, trapezoidal cut screw, trapezoidal reverse ment according to Article 54(3) EPC) discloses the use cut screw, ball screw, kneading paddle, etc., which can of an extruder for the production of solid dispersions. be used in a desired combination. The load fed to the [0005] However, none of these conventional methods 30 extruder is forced by the screw to advance, shorn and are capable of inducing a transition of crystalline state blended by the screw within the barrel structure and expediently, efficiently, uniformly and on a mass scale extruded from the orifice or orifices of the die. Usually, and, therefore, are not well suited for commercial appli- the temperature of each unit barrel and that of the die cation. One of the reasons for their incapability is that can be independently controlled. because these technologies are invariably batch proc- 35 [0010] The extruder is available in two general types, esses, large-scale equipment is required for mass namely a single-screw extruder comprising one screw processing but the larger the equipment, the greater is and a multi-screw extruder comprising two or more the temperature gradient created in the processing screws. While this invention can be carried into practice load, so that homogeneous crystals cannot be easily using either type of extruder, the use of a multi-screw obtained. Taking the recrystallization process as an 40 extruder, particularly a twin-screw extruder, is preferred. example, judicious selection of the recrystallization sol- Compared with a single-screw version, a twin-screw vent, detailed analysis of recrystallizing temperature extruder is more efficient in that the plural screws inter- and other parameters, and accurate control of recrystal- ferring with each other precludes follow-up movement of lization conditions are essential. In the case of freeze- the active substance and, moreover, the intermeshing drying, the protracted processing time is also a detract- 45 of the screws provides a high energy output physically, ing factor. thus assisting in the induction of a transition of crystal- line state. DISCLOSURE OF INVENTION [0011] In the practice of this invention, such an extruder as is in routine use by food industry can be uti- [0006] The object of this invention is to provide a 50 lized as it is. method of inducing a transition of crystalline state in a [0012] The mode of use of the extruder in the practice crystallizable medicinal substance which overcomes of this invention is now described, referring to specific the disadvantages of the above-mentioned prior art embodiments. methods. Specifically, the invention has for its object to [0013] For example, in this invention, the main part of provide a method of inducing, expediently, efficiently, 55 the extruder can be utilized as divided into two zones, uniformly, continuously and on a high production scale, namely a melting zone and a cooling zone as illustrated a transition of crystalline state, for example: in Fig. 2. The melting zone is the zone in which the medicinal substance is melted and the cooling zone is 2 34EP 0 665 009 B1 the zone in which the medicinal substance melted in ambient temperature, while the medicinal sub- said melting zone is solidified. stance fails to crystallize at times when the setting [0014] In the practice of this invention, the melting exceeds the melting-start temperature of stable zone can be defined by one or more barrels. If and when crystals of the medicinal substance. There are the medicinal material can be successfully melted, even 5cases in which a transition to stable crystalline state a single barrel can serve as the melting zone. However, can be obtained even when the setting is below the proper number of barrels defining the melting zone ambient temperature and such cases also fall is dependent on the melting point of the medicinal sub- within the scope of this invention. stance, the crystalline state of said substance, the con- It is true that the higher the cooling zone tem- dition of the substance, the type and ratings of the 10 perature, the greater is the safety with which a extruder used, the rotational speed of the screw (which medicinal substance can be crystallized. However, corresponds to the speed at which the medicinal load although it depends on physical properties of the travels within the barrel), screw geometry (which is medicinal substance, a higher cooling zone temper- related to the pulverization of the medicinal substance) ature setting may call for an increase in the overall and so on. For the processing of a medicinal substance 15 length of the barrel defining the cooling zone or a having a high melting point, in the case where the reduction in the rotational speed of the screw. In medicinal substance is crystalline or coarse, or for either case, processing efficiency tends to be sacri- increasing the rotational speed of the screw, the number ficed. On the other hand, it is not recommendable, of barrels constituting the melting zone may have to be either, to use an unnecessarily low cooling zone increased. 20 temperature. If the cooling zone temperature set- [0015] In the practice of this invention, the tempera- ting is too low, an amorphous solid may result or the ture of the barrel or barrels constituting the melting zone crystals may become heterogenous. Therefore, in (hereafter referred to as 'melting zone temperature') can order to insure an efficient and safe working of this be set to the meltable temperature of the medicinal sub- invention, the cooling zone temperature is prefera- stance.
Load more

Recommended publications
  • Ophthalmic Adverse Effects of Nasal Decongestants on an Experimental
    A RQUIVOS B RASILEIROS DE ORIGINAL ARTICLE Ophthalmic adverse effects of nasal decongestants on an experimental rat model Efeitos oftálmicos adversos de descongestionantes nasais em modelo experimental com ratos Ayse Ipek Akyuz Unsal1, Yesim Basal2, Serap Birincioglu3, Tolga Kocaturk1, Harun Cakmak1, Alparslan Unsal4, Gizem Cakiroz5, Nüket Eliyatkın6, Ozden Yukselen7, Buket Demirci5 1. Department of Ophthalmology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 2. Department of Otorhinolaringology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 3. Department of Pathology, Veterinary Faculty, Adnan Menderes University, Aydin, Turkey. 4. Department of Radiology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 5. Department of Medical Pharmacology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 6. Department of Medical Pathology, Medical Faculty, Adnan Menderes University, Aydin, Turkey. 7. Department of Pathology, Aydin State Hospital, Aydin, Turkey. ABSTRACT | Purpose: To investigate the potential effects of cause ophthalmic problems such as dry eyes, corneal edema, chronic exposure to a nasal decongestant and its excipients cataracts, retinal nerve fiber layer, and vascular damage in on ocular tissues using an experimental rat model. Methods: rats. Although these results were obtained from experimental Sixty adult male Wistar rats were randomized into six groups. animals, ophthalmologists should keep in mind the potential The first two groups were control (serum physiologic) and ophthalmic adverse effects of this medicine and/or its excipients Otrivine® groups. The remaining four groups received the and exercise caution with drugs containing xylometazoline, Otrivine excipients xylometazoline, benzalkonium chloride, ethylene diamine tetra acetic acid, benzalkonium chloride and sorbitol, and ethylene diamine tetra acetic acid. Medications sorbitol for patients with underlying ocular problems.
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • ERJ-01090-2018.Supplement
    Shaheen et al Online data supplement Prescribed analgesics in pregnancy and risk of childhood asthma Seif O Shaheen, Cecilia Lundholm, Bronwyn K Brew, Catarina Almqvist. 1 Shaheen et al Figure E1: Data available for analysis Footnote: Numbers refer to adjusted analyses (complete data on covariates) 2 Shaheen et al Table E1. Three classes of analgesics included in the analyses ATC codes Generic drug name Opioids N02AA59 Codeine, combinations excluding psycholeptics N02AA79 Codeine, combinations with psycholeptics N02AA08 Dihydrocodeine N02AA58 Dihydrocodeine, combinations N02AC04 Dextropropoxyphene N02AC54 Dextropropoxyphene, combinations excluding psycholeptics N02AX02 Tramadol Anti-migraine N02CA01 Dihydroergotamine N02CA02 Ergotamine N02CA04 Methysergide N02CA07 Lisuride N02CA51 Dihydroergotamine, combinations N02CA52 Ergotamine, combinations excluding psycholeptics N02CA72 Ergotamine, combinations with psycholeptics N02CC01 Sumatriptan N02CC02 Naratriptan N02CC03 Zolmitriptan N02CC04 Rizatriptan N02CC05 Almotriptan N02CC06 Eletriptan N02CC07 Frovatriptan N02CX01 Pizotifen N02CX02 Clonidine N02CX03 Iprazochrome N02CX05 Dimetotiazine N02CX06 Oxetorone N02CB01 Flumedroxone Paracetamol N02BE01 Paracetamol N02BE51 Paracetamol, combinations excluding psycholeptics N02BE71 Paracetamol, combinations with psycholeptics 3 Shaheen et al Table E2. Frequency of analgesic classes prescribed to the mother during pregnancy Opioids Anti- Paracetamol N % migraine No No No 459,690 93.2 No No Yes 9,091 1.8 Yes No No 15,405 3.1 No Yes No 2,343 0.5 Yes No
    [Show full text]
  • Pharmacokinetic Drug–Drug Interactions Among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients
    International Journal of Molecular Sciences Review Pharmacokinetic Drug–Drug Interactions among Antiepileptic Drugs, Including CBD, Drugs Used to Treat COVID-19 and Nutrients Marta Kara´zniewicz-Łada 1 , Anna K. Główka 2 , Aniceta A. Mikulska 1 and Franciszek K. Główka 1,* 1 Department of Physical Pharmacy and Pharmacokinetics, Poznan University of Medical Sciences, 60-781 Pozna´n,Poland; [email protected] (M.K.-Ł.); [email protected] (A.A.M.) 2 Department of Bromatology, Poznan University of Medical Sciences, 60-354 Pozna´n,Poland; [email protected] * Correspondence: [email protected]; Tel.: +48-(0)61-854-64-37 Abstract: Anti-epileptic drugs (AEDs) are an important group of drugs of several generations, rang- ing from the oldest phenobarbital (1912) to the most recent cenobamate (2019). Cannabidiol (CBD) is increasingly used to treat epilepsy. The outbreak of the SARS-CoV-2 pandemic in 2019 created new challenges in the effective treatment of epilepsy in COVID-19 patients. The purpose of this review is to present data from the last few years on drug–drug interactions among of AEDs, as well as AEDs with other drugs, nutrients and food. Literature data was collected mainly in PubMed, as well as google base. The most important pharmacokinetic parameters of the chosen 29 AEDs, mechanism of action and clinical application, as well as their biotransformation, are presented. We pay a special attention to the new potential interactions of the applied first-generation AEDs (carba- Citation: Kara´zniewicz-Łada,M.; mazepine, oxcarbazepine, phenytoin, phenobarbital and primidone), on decreased concentration Główka, A.K.; Mikulska, A.A.; of some medications (atazanavir and remdesivir), or their compositions (darunavir/cobicistat and Główka, F.K.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/014.3507 A1 Gant Et Al
    US 2010.0143507A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/014.3507 A1 Gant et al. (43) Pub. Date: Jun. 10, 2010 (54) CARBOXYLIC ACID INHIBITORS OF Publication Classification HISTONE DEACETYLASE, GABA (51) Int. Cl. TRANSAMINASE AND SODIUM CHANNEL A633/00 (2006.01) A 6LX 3/553 (2006.01) A 6LX 3/553 (2006.01) (75) Inventors: Thomas G. Gant, Carlsbad, CA A63L/352 (2006.01) (US); Sepehr Sarshar, Cardiff by A6II 3/19 (2006.01) the Sea, CA (US) C07C 53/128 (2006.01) A6IP 25/06 (2006.01) A6IP 25/08 (2006.01) Correspondence Address: A6IP 25/18 (2006.01) GLOBAL PATENT GROUP - APX (52) U.S. Cl. .................... 424/722:514/211.13: 514/221; 10411 Clayton Road, Suite 304 514/456; 514/557; 562/512 ST. LOUIS, MO 63131 (US) (57) ABSTRACT Assignee: AUSPEX The present invention relates to new carboxylic acid inhibi (73) tors of histone deacetylase, GABA transaminase, and/or PHARMACEUTICALS, INC., Sodium channel activity, pharmaceutical compositions Vista, CA (US) thereof, and methods of use thereof. (21) Appl. No.: 12/632,507 Formula I (22) Filed: Dec. 7, 2009 Related U.S. Application Data (60) Provisional application No. 61/121,024, filed on Dec. 9, 2008. US 2010/014.3507 A1 Jun. 10, 2010 CARBOXYLIC ACID INHIBITORS OF HISTONE DEACETYLASE, GABA TRANSAMNASE AND SODIUM CHANNEL 0001. This application claims the benefit of priority of Valproic acid U.S. provisional application No. 61/121,024, filed Dec. 9, 2008, the disclosure of which is hereby incorporated by ref 0004 Valproic acid is extensively metabolised via erence as if written herein in its entirety.
    [Show full text]
  • Article (Published Version)
    Article Characterization of drug‐induced transcriptional modules: towards drug repositioning and functional understanding ISKAR, Murat, et al. Reference ISKAR, Murat, et al. Characterization of drug‐induced transcriptional modules: towards drug repositioning and functional understanding. Molecular Systems Biology, 2013, vol. 9, no. 1, p. 662 DOI : 10.1038/msb.2013.20 PMID : 23632384 Available at: http://archive-ouverte.unige.ch/unige:153825 Disclaimer: layout of this document may differ from the published version. 1 / 1 Molecular Systems Biology 9; Article number 662; doi:10.1038/msb.2013.20 Citation: Molecular Systems Biology 9:662 www.molecularsystemsbiology.com Characterization of drug-induced transcriptional modules: towards drug repositioning and functional understanding Murat Iskar1, Georg Zeller1, Peter Blattmann2,3, Monica Campillos4,5, Michael Kuhn6, Katarzyna H Kaminska1,9, Heiko Runz3,7, Anne-Claude Gavin1, Rainer Pepperkok2,3, Vera van Noort1 and Peer Bork1,8,* 1 Structural and Computational Biology Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany, 2 Cell Biology/Biophysics Unit, EMBL, Heidelberg, Germany, 3 Molecular Medicine Partnership Unit (MMPU), EMBL, University of Heidelberg, Heidelberg, Germany, 4 Institute for Bioinformatics and Systems Biology, Helmholtz Center Munich–German Research Center for Environmental Health (GmbH), Neuherberg, Germany, 5 German Center for Diabetes Research (DZD), Neuherberg, Germany, 6 Biotechnology Center, TU Dresden, Dresden, Germany, 7 Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany and 8 Max-Delbru¨ck-Centre for Molecular Medicine, Berlin, Germany 9Present address: International Institute of Molecular and Cell Biology in Warsaw, ul. Ks. Trojdena 4, 02-109 Warsaw, Poland * Corresponding author. Structural and Computational Biology Unit, European Molecular Biology Laboratory (EMBL), Meyerhofstrasse 1, Heidelberg, Germany.
    [Show full text]